Abiomed (ABMD) Tops Q2 EPS by 6c

October 28, 2021 7:03 AM EDT

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $1.03, $0.06 better than the analyst estimate of $0.97. Revenue for the quarter came in at $248.1 million versus the consensus estimate of $247.66 million.

GUIDANCE:

Abiomed sees FY2022 revenue of $1.01-1.03 billion, versus the consensus of $1.04 billion.

For earnings history and earnings-related data on Abiomed (ABMD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings